Basic Information
RNALocate ID: | RLID:01002694 |
RNA Symbol: | hsa-miR-708-5p |
Localization: | Mitochondrion |
RNA Information
RNA Name: | hsa-miR-708 |
RNA ID: | miRBase:MIMAT0004926 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21637849 |
Tissue/Cell Line: | Skeletal muscle myoblasts |
Method: | ISH|qRT-PCR |
Description: | List of microRNA significantly detected in the mitochondrial mRNA at three increasing mtRNA inputs (1, 5 and 35 uL). Table S3 List of microRNA significantly detected (Cp<35) in the mitochondrial mRNA at the two highest mtRNA inputs (5 and 35 uL). Data are collected from Table 4 and S3. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002695 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:11004120 | Exosome | Plasma | 23663360 |
RLID:11004121 | Microvesicle | Cerebrospinal fluid | 24797360 |
RLID-D:11000717 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
RLID-D:11001599 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-708-5p | Oral squamous cell carcinoma | MNDR-E-MI-68056 |
MNDR | hsa-miR-708-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-68057 |
MNDR | hsa-miR-708-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-68058 |
MNDR | hsa-miR-708-5p | Ovarian clear cell carcinoma | MNDR-E-MI-68059 |
MNDR | hsa-miR-708-5p | Lymphoma | MNDR-E-MI-68060 |
MNDR | hsa-miR-708-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-68061 |
MNDR | hsa-miR-708-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-68062 |
MNDR | hsa-miR-708-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-68063 |
MNDR | hsa-miR-708-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-68064 |
MNDR | hsa-miR-708-5p | Her2-receptor positive breast cancer | MNDR-E-MI-68065 |
MNDR | hsa-miR-708-5p | Breast cancer luminal | MNDR-E-MI-68066 |
MNDR | hsa-miR-708-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-68067 |
MNDR | hsa-miR-708-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-68068 |
MNDR | hsa-miR-708-5p | Small intestine cancer | MNDR-E-MI-68069 |
MNDR | hsa-miR-708-5p | Prostate cancer | MNDR-E-MI-68070 |
MNDR | hsa-miR-708-5p | Chronic lymphocytic leukemia | MNDR-E-MI-68071 |
MNDR | hsa-miR-708-5p | Gastric cancer | MNDR-E-MI-68072 |
MNDR | hsa-miR-708-5p | Alzheimer disease | MNDR-E-MI-68073 |
MNDR | hsa-miR-708-5p | Urinary bladder cancer | MNDR-E-MI-68074 |
MNDR | hsa-miR-708-5p | Esophageal carcinoma | MNDR-E-MI-68075 |
MNDR | hsa-miR-708-5p | Dysautonomia familial | MNDR-E-MI-68076 |
MNDR | hsa-miR-708-5p | Graves disease | MNDR-E-MI-68077 |
MNDR | hsa-miR-708-5p | Leukemia | MNDR-E-MI-68078 |
MNDR | hsa-miR-708-5p | Huntington disease | MNDR-E-MI-68079 |
MNDR | hsa-miR-708-5p | Lung cancer | MNDR-E-MI-68080 |
MNDR | hsa-miR-708-5p | Parkinson disease | MNDR-E-MI-68081 |
MNDR | hsa-miR-708-5p | Primary pulmonary hypertension | MNDR-E-MI-68082 |
MNDR | hsa-miR-708-5p | Basal-like breast cancer | MNDR-E-MI-68083 |
MNDR | hsa-miR-708-5p | Cancer | MNDR-E-MI-68084 |
MNDR | hsa-miR-708-5p | Thyroid cancer | MNDR-E-MI-68085 |
MNDR | hsa-miR-708-5p | Pancreatic cancer | MNDR-E-MI-68086 |
MNDR | hsa-miR-708-5p | Rectum adenocarcinoma | MNDR-E-MI-68087 |
MNDR | hsa-miR-708-5p | Nephroblastoma | MNDR-E-MI-68088 |
MNDR | hsa-miR-708-5p | Colon cancer | MNDR-E-MI-68089 |
MNDR | hsa-miR-708-5p | Colon adenocarcinoma | MNDR-E-MI-68090 |
MNDR | hsa-miR-708-5p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-68091 |
MNDR | hsa-miR-708-5p | Prostate adenocarcinoma | MNDR-E-MI-68092 |
MNDR | hsa-miR-708-5p | Laryngeal neoplasms | MNDR-E-MI-68093 |
MNDR | hsa-miR-708-5p | Endometriosis | MNDR-E-MI-68094 |
MNDR | hsa-miR-708-5p | Carcinoma ductal breast | MNDR-E-MI-68095 |
MNDR | hsa-miR-708-5p | Glioblastoma | MNDR-E-MI-68096 |
MNDR | hsa-miR-708-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-68097 |
MNDR | hsa-miR-708-5p | Ewing sarcoma | MNDR-E-MI-68098 |
MNDR | hsa-miR-708-5p | Gastric adenocarcinoma | MNDR-E-MI-68099 |
MNDR | hsa-miR-708-5p | Lung squamous cell carcinoma | MNDR-E-MI-68100 |
MNDR | hsa-miR-708-5p | Carcinoma lung non-small-cell | MNDR-E-MI-68101 |
MNDR | hsa-miR-708-5p | Lung adenocarcinoma | MNDR-E-MI-68102 |
MNDR | hsa-miR-708-5p | Thyroid carcinoma | MNDR-E-MI-68103 |
MNDR | hsa-miR-708-5p | Ovarian carcinoma | MNDR-E-MI-68104 |
MNDR | hsa-miR-708-5p | Bladder urothelial carcinoma | MNDR-E-MI-68105 |
MNDR | hsa-miR-708-5p | Pancreatic adenocarcinoma | MNDR-E-MI-68106 |
MNDR | hsa-miR-708-5p | Carcinoma renal cell | MNDR-E-MI-68107 |
MNDR | hsa-miR-708-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-68108 |
MNDR | hsa-miR-708-5p | Renal clear cell carcinoma | MNDR-E-MI-68109 |
MNDR | hsa-miR-708-5p | Biliary tract cancer | MNDR-E-MI-68110 |
MNDR | hsa-miR-708-5p | Cholangiocarcinoma | MNDR-E-MI-68111 |
MNDR | hsa-miR-708-5p | Esophageal cancer | MNDR-E-MI-68112 |
MNDR | hsa-miR-708-5p | Synovial sarcoma | MNDR-E-MI-68113 |
MNDR | hsa-miR-708-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-68114 |
MNDR | hsa-miR-708-5p | Breast invasive carcinoma | MNDR-E-MI-68115 |
MNDR | hsa-miR-708-5p | Hepatocellular carcinoma | MNDR-E-MI-68116 |
MNDR | hsa-miR-708-5p | Hodgkin lymphoma | MNDR-E-MI-68117 |
MNDR | hsa-miR-708-5p | Colorectal cancer | MNDR-E-MI-68118 |
MNDR | hsa-miR-708-5p | Nasopharynx carcinoma | MNDR-E-MI-68119 |
MNDR | hsa-miR-708-5p | Multiple myeloma | MNDR-E-MI-68120 |
MNDR | hsa-miR-708-5p | Nasopharyngeal cancer | MNDR-E-MI-68121 |
MNDR | hsa-miR-708-5p | Prostatic neoplasms | MNDR-E-MI-68122 |
MNDR | hsa-miR-708-5p | Aids dementia complex | MNDR-E-MI-68123 |
MNDR | hsa-miR-708-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-68124 |
MNDR | hsa-miR-708-5p | Breast cancer her3+ negative | MNDR-E-MI-68125 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | AKT1 | Homo sapiens | RR00067020 |
TOP